AGT and respiratory tract infectious disorder: Bisartans have the potential to be effective against respiratory infections in two ways: (i) by reducing the negative effects of pathogenic RAS components (e.g., angiotensin II (AngII)), such as pulmonary edema, inflammation, and cytokine storm, and (ii) by blocking interactions between the ACE2 receptor and the S-protein of the virus.